GKOS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Glaukos Corporation

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
CEO
Thomas Burns
Employees
653
Headquarters

229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com

News

Keratoconus Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix
Jul 11, 2024 18:55pm

DelveInsight''s "Keratoconus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Keratoconus, historical and forecasted epidemiology as well as the Keratoconus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and


Source:OpenPR
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
Jul 10, 2024 11:00am

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 financial results after the market close on Wednesday, July 31, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Here''s Why You Should Retain Glaukos Stock for Now
Jul 03, 2024 17:45pm

Glaukos Corporation (NYSE: GKOS ) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry''s 5.4% growth. The S&P 500 Index has also increased 15% in the same time frame. Glaukos, with a market capitalization of $5.91 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 1.3% for 2024, followed by 43.1% growth in 2025, and expects to maintain its strong performance in terms of revenues as well. The company has a trailing four-quarter average negative earnings surprise of 4.74%. Image Source: Zacks Investment Research Key Catalysts In 2023, Glaukos witnessed sales returning to growth after experiencing a downturn in 2022. This positive shift can be attributed to a more favorable macroeconomic climate and the introduction of a series of new products in recent quarters.


Source:Benzinga
Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?
Jun 27, 2024 10:03am

Glaukos (GKOS) shares rallied 3.7% in the last trading session to close at $116.66. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…


Source:BankBit
Glaukos Corp president and COO sells over $280k in stock
Jun 05, 2024 23:38pm

https://www.investing.com/news/company-news/glaukos-corp-president-and-coo-sells-over-280k-in-stock-93CH-3472824


Source:Investing.com
Glaukos Governance and Compensation Strategy Evolves
Jun 05, 2024 12:02pm

An update from Glaukos (GKOS) is now available. Glaukos Corporation’s Board of Directors implemented the amended 2015 Omnibus Incentive Compensatio…


Source:TipRanks
Adult Myopia Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight
May 28, 2024 14:58pm

Adult myopia companies are ORA, Inc., LENZ Therapeutics, Inc, Glaukos Corporation, Vyluma, Inc., Sydnexis, Ocumension limited, Santen Pharmaceutical, and more. ALBANY, NEW YORK, UNITED STATES, May 28, 2024 /⁨EINPresswire.com⁩/ -- DelveInsight’s …


Source:EIN News Healthcare